Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zonisamide - Eisai Co Ltd

Drug Profile

Zonisamide - Eisai Co Ltd

Alternative Names: AD-810; AD-810N; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran

Latest Information Update: 31 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Concordia Pharmaceuticals; Dainippon Sumitomo Pharma; Eisai Co Ltd; Sumitomo Dainippon Pharma
  • Class Antidementias; Antiepileptic drugs; Isoxazoles
  • Mechanism of Action Antioxidants; Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Parkinson's disease
  • Registered Lewy body disease
  • Discontinued Cerebral ischaemia; Manic episodes; Migraine; Neuropathic pain; Obesity

Most Recent Events

  • 02 Jul 2018 Registered for Lewy body disease in Japan (PO, Fast dissolving tablet)
  • 02 Jul 2018 Registered for Lewy body disease in Japan (PO, Tablet)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top